Veradermics reports topline results from Phase 2/3 trial of VDPHL01, showing efficacy in male pattern hair loss

Veradermics announced topline results from its registration-directed Phase 2/3 trial of VDPHL01, demonstrating efficacy in male pattern hair loss. The company scheduled an investor call for November 9, 2026 at 8:00 am ET to review the results.

Detected & updated continuously · Source: Nebula